Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.240
Sell
RSI(14)
42.630
Neutral
STOCH(KDJ)(9,3,3)
35.340
Neutral
ATR(14)
1.069
Low Volatility
CCI(14)
-53.097
Neutral
Williams %R
78.616
Sell
TRIX(12,20)
-0.614
Sell
StochRSI(14)
38.023
Sell
NextCure Inc
NXTC11.100USD
+0.010+0.09%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
29.70MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of NextCure Inc
Currency: USD Updated: 2026-02-06Key Insights
NextCure Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.67.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NextCure Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
NextCure Inc Highlights
StrengthsRisks
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Fairly Valued
The company’s latest PE is -0.47, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 903.98K shares, decreasing 36.33% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 91.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.86.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
17.667
Target Price
+59.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of NextCure Inc is 6.27, ranking 273 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
5.87
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.86
Operational Efficiency
3.86
Growth Potential
6.75
Shareholder Returns
7.03
NextCure Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of NextCure Inc is 7.28, ranking 141 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.47, which is -99.57% below the recent high of -0.00 and -133.60% above the recent low of -1.09.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 128/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of NextCure Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 20.00 and a low of 15.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
17.667
Target Price
+59.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
NextCure Inc
NXTC
3
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of NextCure Inc is 7.04, ranking 113 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.33 and the support level at 9.65, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
11.228
Sell
MA10
11.143
Sell
MA20
12.056
Sell
MA50
12.326
Sell
MA100
10.342
Buy
MA200
7.879
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of NextCure Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 33.74%, representing a quarter-over-quarter increase of 4.66%. The largest institutional shareholder is The Vanguard, holding a total of 91.91K shares, representing 3.43% of shares outstanding, with 2.71% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Simcere Zaiming, Inc
Affinity Asset Advisors LLC
Sofinnova Investments, Inc
Squadron Capital Management LLC
Pfizer Inc
Cable Car Capital LLC
Acadian Asset Management LLC
Richman (Michael S)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of NextCure Inc is 1.56, ranking 304 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.54
VaR
+6.41%
240-Day Maximum Drawdown
+65.34%
240-Day Volatility
+285.73%
Return
Best Daily Return
60 days
+34.25%
120 days
+37.13%
5 years
+37.13%
Worst Daily Return
60 days
-8.85%
120 days
-23.41%
5 years
-26.27%
Sharpe Ratio
60 days
+1.33
120 days
+1.91
5 years
-0.29
Risk Assessment
Maximum Drawdown
240 days
+65.34%
3 years
+89.16%
5 years
+97.03%
Return-to-Drawdown Ratio
240 days
+21.12
3 years
+2.29
5 years
+0.05
Skewness
240 days
+0.97
3 years
+0.85
5 years
+0.71
Volatility
Realised Volatility
240 days
+285.73%
5 years
+146.26%
Standardised True Range
240 days
+5.71%
5 years
+2.43%
Downside Risk-Adjusted Return
120 days
+335.62%
240 days
+335.62%
Maximum Daily Upside Volatility
60 days
+115.44%
Maximum Daily Downside Volatility
60 days
+65.31%
Liquidity
Average Turnover Rate
60 days
+0.90%
120 days
+0.76%
5 years
--
Turnover Deviation
20 days
-85.82%
60 days
+74.10%
120 days
+47.67%
Peer Comparison
Biotechnology & Medical Research
NextCure Inc
NXTC
6.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
